← back to search

Yaron Ilan

Hebrew University of Jerusalem · IL
Area of research
Epidemiology · Immunology
Research interest
Research interests include Medicine, Regimen, Computer science, Cannabis, Internal medicine, and Biology.
h-index
citations
279
works
13
NIH funding
primary concept
email

Recent publications

The Constrained Disorder Principle: Beyond Biological Allostasis
Biology 2025cited by 7position: lastdoi
A constrained disorder principle-based second-generation artificial intelligence digital medical cannabis system: A real-world data analysis
Journal of public health research 2025cited by 4position: lastdoi
Immune digital twins for complex human pathologies: applications, limitations, and challenges
npj Systems Biology and Applications 2024cited by 66position: middledoi
A Feasibility Open-Labeled Clinical Trial Using a Second-Generation Artificial-Intelligence-Based Therapeutic Regimen in Patients with Gaucher Disease Treated with Enzyme Replacement Therapy
Journal of Clinical Medicine 2024cited by 19position: lastdoi
Improving the response to lenvatinib in partial responders using a Constrained-Disorder-Principle-based second-generation artificial intelligence-therapeutic regimen: a proof-of-concept open-labeled clinical trial
Frontiers in Oncology 2024cited by 16position: middledoi
A second-generation artificial intelligence-based therapeutic regimen improves diuretic resistance in heart failure: Results of a feasibility open-labeled clinical trial
Biomedicine & Pharmacotherapy 2023cited by 38position: lastdoi
The Constrained Disorder Principle Accounts for the Variability That Characterizes Breathing: A Method for Treating Chronic Respiratory Diseases and Improving Mechanical Ventilation
Advances in respiratory medicine 2023cited by 18position: lastdoi
Low-Dose Colchicine Attenuates Sepsis-Induced Liver Injury: A Novel Method for Alleviating Systemic Inflammation
Inflammation 2023cited by 11position: lastdoi
Serum Levels of Adropin Improve the Predictability of MELD and Child-Pugh Score in Cirrhosis: Results of Proof-of-Concept Clinical Trial
Transplant International 2023cited by 4position: lastdoi
Digital Medical Cannabis as Market Differentiator: Second-Generation Artificial Intelligence Systems to Improve Response
Frontiers in Medicine 2022cited by 38position: firstdoi
Improving the effectiveness of anti-aging modalities by using the constrained disorder principle-based management algorithms
Frontiers in Aging 2022cited by 34position: lastdoi
756P Glypican-3 (GPC3) and NKp46 directed FLEX-NK engager antibody (CYT-303) recruits natural killer (NK) cells to tumors in a preclinical hepatocellular carcinoma (HCC) mouse model
Annals of Oncology 2022cited by 3position: middledoi
Attenuating the rate of total body fat accumulation and alleviating liver damage by oral administration of vitamin D-enriched edible mushrooms in a diet-induced obesity murine model is mediated by an anti-inflammatory paradigm shift
BMC Gastroenterology 2017cited by 21position: lastdoi

Grants

No grants ingested yet.

Frequent collaborators

Yotam Kolben · Hebrew University of Jerusalem4 papers (2023–2025)Noa Hurvitz · Hebrew University of Jerusalem4 papers (2022–2025)Marc Berg · Palo Alto University4 papers (2023–2025)Samuel Agus · Palo Alto University4 papers (2023–2025)Asa Kessler · Hebrew University of Jerusalem2 papers (2023–2023) · 2 papers (2022–2024) · 2 papers (2023–2024)Khurram Jamil · Rodin Therapeutics (United States)2 papers (2023–2025)Sarah Weksler‐Zangen · Hebrew University of Jerusalem2 papers (2023–2023)Ofek Adar · Hebrew University of Jerusalem2 papers (2023–2025)Ariel Kenig · Hebrew University of Jerusalem2 papers (2023–2023) · 1 papers (2022–2022)Shoshana Revel‐Vilk · Hebrew University of Jerusalem1 papers (2024–2024)O. Mandelboim · Hebrew University of Jerusalem1 papers (2022–2022) · 1 papers (2022–2022) · 1 papers (2022–2022)Ari Zimran · Hebrew University of Jerusalem1 papers (2024–2024)Ofra Maimon · Hebrew University of Jerusalem1 papers (2024–2024) · 1 papers (2017–2017)Josef Daniel Shakargy · Hebrew University of Jerusalem1 papers (2025–2025)